Elebsiran-tobevibart meets phase 3 hepatitis delta goal; efinopegdutide resolves MASH in phase 2b; dabigatran recanalizes portal vein thrombosis

A flexible endoscope with its control head and two round angulation wheels, its long insertion tube coiling in a loose loop on a table.

Vir Biotechnology said 44% of patients given elebsiran and tobevibart reached undetectable hepatitis delta virus RNA with ALT normalization at week 48 in the phase 3 ECLIPSE 1 trial.

Efinopegdutide resolved MASH in up to 63% of patients versus 13% with placebo in a phase 2b trial, and dabigatran recanalized portal vein thrombosis in 64.3% versus 21.4% with placebo in cirrhosis.

The weekly innovation roundup for gastroenterology, published every Sunday for the week before; every item links to its sources. Latest gastroenterology news · All specialties

Latest news

Tagged gastroenterology, from the daily briefing

  1. PAVmed says Medicare now pays for the EsoGuard esophageal precancer test nationwide
  2. Izalontamab brengitecan vs chemotherapy in advanced esophageal squamous cell carcinoma, a 497-patient phase 3 trial
  3. Dabigatran achieved complete recanalization in 64.3% vs 21.4% with placebo in cirrhosis with portal vein thrombosis

See all the latest news